PROTHENA CORP PUBLIC LTD CO, commonly known as Prothena, is publicly traded under the ticker symbol PRTA. It is a biotechnological company that predominantly focuses on the discovery, development, and commercialization of novel therapies designed to combat life-threatening diseases in the field of neuroscience. Prothena is specifically committed to targeting proteins dysfunctions that may lead to devastating neurodegenerative conditions.
The company was established with a vision to establish transformative therapies for patients with neurodegenerative disorders and initiate a new wave of effective treatments for these debilitating diseases. The diseases targeted by Prothena’s research are often associated with abnormal deposition of misfolded proteins, such as Parkinson’s and Alzheimer’s diseases, Amyotrophic Lateral Sclerosis (ALS), and Peripheral Neuropathy.
Prothena's portfolio includes a diverse range of therapeutic antibodies, made possible by its proprietary discovery engine and approach to protein dysfunctions. One of its lead pipeline candidates, PRX002/RG7935, targets the alpha-synuclein protein associated with Parkinson's disease and is being developed in collaboration with the global biopharmaceutical company, Roche.
The company strives to improve patient outcomes and the quality of life for those affected by neurodegenerative diseases, and it underscores the importance of innovation and scientific discovery. Prothena’s team comprises a broad range of scientific and clinical experts who utilise their aptitudes to create life-changing treatments.
Prothena is based in Dublin, Ireland, but has expanded to have a significant presence in the United States, specifically in the San Francisco Bay Area. As a public limited company (PLC), Prothena shares are floated on public exchanges, enabling investors to buy in and support the company's ambitions and progress.
Beyond its commitment to innovative R&D, Prothena values strong corporate governance and is dedicated to operating with integrity. This includes adhering to strict ethical guidelines, managing resources wisely, and being transparent with investors and stakeholders.
In summary, Prothena Corp Public Ltd Co is an innovative biotechnology firm committed to creating transformative therapies for serious and often rare neurodegenerative diseases. Its extensive research, strategic collaborations, and dedication to integrity play a part in its steadfast journey towards its vision of improving the lives of patients by easing the burdens they face.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA), indicating stable neutral readings in shorter horizons may signal an easing of a long-term weak bias. It highlights a mid-channel oscillation pattern and presents an exceptional 35.7:1 risk-reward short setup. The analysis provides AI-generated institutional trading strategies for long, breakout, and short positions, along with multi-timeframe signal analysis and support/resistance levels.
This article provides a detailed AI-driven analysis of Prothena Corporation Plc (NASDAQ: PRTA), highlighting a positive near-term sentiment that may be shifting due to broader weak alignment and a mid-channel oscillation pattern. It presents an exceptional 36.0:1 risk-reward short setup and outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Prothena Corp Public Ltd insider William P Scully, a 10% owner, purchased 103,500 shares of the company on September 28, 2026. This transaction is detailed in a recent SEC filing. The article indicates that a premium subscription is required to read the full details of this MT Newswires report.
William P Scully, a 10% owner of Prothena Corp Public Ltd, purchased 100,000 shares of the company's stock on September 18, 2026. This transaction was valued at $843,460, according to a recent SEC filing. The article highlights this insider buying activity.
Prothena Corporation plc (NASDAQ: PRTA), a clinical biotechnology company, announced that its senior management team will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled for Wednesday, September 16, 2026, at 8:30 a.m. ET in New York, NY. A live webcast and replay will be available through the investor relations section of the Company's website.
Prothena Corporation plc announced that its senior management team will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. The event will be held in New York, NY, and a live webcast will be available on the company's investor relations website, with a replay accessible for 90 days afterward. Prothena is a late-stage clinical biotechnology company focusing on neurodegenerative and rare peripheral amyloid diseases.